AssetMark Inc’s Blueprint Medicines BPMC Stock Holding History

AssetMark Inc’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40	Closed	-$5.13K	–	3191
2025 Q2	$5.13K	Buy	40 +23	+135%	+$2.39K	﹤0.01%	2131
2025 Q1	$1.5K	Buy	17 +3	+21%	+$293	﹤0.01%	2228
2024 Q4	$1.22K	Buy	14 +8	+133%	+$733	﹤0.01%	2209
2024 Q3	$555	Buy	6 +3	+100%	+$298	﹤0.01%	2073
2024 Q2	$323	Sell	3 -3	-50%	-$300	﹤0.01%	1969
2024 Q1	$569	Buy	+6	New	+$515	﹤0.01%	1716
2020 Q1	–	Sell	-18	Closed	-$1K	–	1371
2019 Q4	$1K	Hold	18	–	–	﹤0.01%	1294
2019 Q3	$1K	Buy	+18	New	+$1.56K	﹤0.01%	1219

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AssetMark Inc's BPMC Position: Q3 2025 in Review

AssetMark Inc sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 40 shares — an estimated $5.13K sold.

AssetMark Inc first reported a position in BPMC in Q3 2019 and held it in 8 quarters. The position peaked at $5.13K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

AssetMark Inc reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
AssetMark Inc sold 40 Blueprint Medicines shares in Q3 2025, an estimated $5.13K.
AssetMark Inc first reported a position in Blueprint Medicines in Q3 2019 and held it in 8 quarters.
AssetMark Inc's Blueprint Medicines position peaked at $5.13K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on AssetMark Inc's 13F filing for Q3 2025, filed 6 Nov 2025.